Uneven pigment — sun spots, melasma, the dark marks left after acne or a procedure — is one of the most heavily researched problems in cosmetic dermatology. Peptides are a small and recent part of that research. This page counts where they sit in it, as of 22 October 2026, and reads the few studies that put a peptide cream against one without it. It ranks no product and gives no advice on treatment; pigment disorders, melasma in particular, are a reason to see a dermatologist.
The size of the field, and the peptides' share
PubMed returned 12,246 records with hyperpigmentation or melasma in the title or abstract on 22 October 2026, and 697 randomized controlled trials. Against that background:
| Search, within hyperpigmentation or melasma RCTs | Trials |
|---|---|
| Hydroquinone | 118 |
| Tranexamic acid | 75 |
| Niacinamide | 14 |
| Azelaic acid | 10 |
Any peptide (peptide* in title or abstract) |
5 |
The five “peptide” trials are a mixed set, and only one of them is a test of a peptide's effect on pigment against its absence:
- Tetrapeptide-30 (PKEK), 2011 — vehicle-controlled, double-blind, people with skin types V–VI in South Africa with melasma or post-inflammatory marks; the peptide formula beat the vehicle at 12 weeks on overall appearance and evenness of tone. The authors were at Evonik, the supplier (PMID 21896134; detail on our tetrapeptide-30 page).
- Rice peptides with ascorbyl tetraisopalmitate, 2021 — 60 women aged 20 to 30, sunscreens and formulations against placebo; reduced hyperpigmentation is reported for the combination, which cannot be split into its parts (PMID 33529350).
- Defensin regimen, 2018 — 44 women on a three-product serum, cream and mask regimen against placebo; pigmentation is one of several outcomes reported as improved (PMID 29601620).
- Epidermal growth factor after laser, 2018 — the one negative result, below (PMID 29956440).
- A “multi-component reaction peptide”, 2024 — L'Oréal's post-laser healing study on forearm wounds in 20 people against Aquaphor; its pigment findings are laboratory ones, and the human endpoint was wound healing (PMID 37924217).
Three controlled comparisons
Widening the search beyond the RCT tag finds two more studies that compare a peptide cream with one lacking it. With PKEK, they are the whole of the controlled human record for a cosmetic peptide on pigment:
| Peptide | Study | Design | Result as reported |
|---|---|---|---|
| Tetrapeptide-30 (PKEK) | Farwick et al. 2011, Evonik | Double-blind, vehicle-controlled; skin types V–VI | Better than vehicle at 12 weeks on overall appearance (p < 0.05) and evenness (p < 0.01); participant number not in the abstract |
| PTPD-12 (pentasodium tetracarboxymethyl palmitoyl dipeptide-12) | Bae et al. 2025, Yonsei University | Randomized split-face, 8 weeks, 21 people, control cream on the other side | Melanin index on the treated side 216.9 → 194.7; investigator score 1.78 vs 1.28 (p = 0.0011) and patient score 2.05 vs 1.25 (p = 0.0020) in the peptide side's favour; less melanin on skin staining; no significant side effects; authors declared no conflicts |
| Decapeptide-12 (Lumixyl) | Split-face trial in five women | Randomized split-face | Summarised on our decapeptide-12 page, with the rest of its record, which is mostly a four-product system |
PTPD-12 is the newest and the only one of the three tested by a university group with no declared ties. It is described as an autophagy-inducing peptide — one that prompts cells to break down and recycle their own components — and the same molecule had earlier been tested in a moisturiser for eczema (counted on our peptides and eczema page). Twenty-one people for eight weeks is a pilot, and the abstract reports the treated side's melanin change without giving the control side's for comparison.
The combination studies
Most peptide pigmentation work tests a peptide inside a regimen, which tells a reader about the regimen:
- Oligopeptide-68, a peptide modelled on the signalling protein TGF-β1, has two PubMed records. A 2016 Thai study gave 40 women a night serum with diacetyl boldine and a day cream with diacetyl boldine, oligopeptide-68 and sunscreen, double-blind, for 12 weeks; melasma scores improved from baseline, and the comparison with 2% and 4% hydroquinone was made on normal skin of the arms (PMID 26833454). A 2020 Italian study of 20 women used oligopeptide-68 with glycolic, lactic and phytic acids and the sunscreen filter octinoxate, with no comparison group (PMID 33133340). Acids and sunscreen both lighten pigment in their own right.
- Nonapeptide-1 is usually cited for brightening, but in its best-known study it is the targeting tag on a nanoparticle rather than the active (see our nonapeptide-1 page).
The one clearly negative test
After fractional CO2 laser resurfacing, dark marks are a common complication in darker skin. A 2018 split-face trial at Siriraj Hospital in Bangkok gave 19 people, mostly skin types III–V, an epidermal growth factor ointment on one cheek and petrolatum on the other. Post-inflammatory hyperpigmentation appeared on 52.6% of growth-factor sides and 57.9% of petrolatum sides (p = 0.56), and the melanin index did not differ (p = 0.96). Growth factors are peptides, and this is the one controlled test of one against marks after a procedure. It found no clear benefit.
The laboratory pipeline
The rest of the 33 records that join peptides to pigmentation and a topical form are mostly early: peptides from silk, spirulina, Siamese-crocodile serum and frog skin, designed tyrosinase inhibitors, and liposome carriers, tested on pigment cells, skin models or mouse ears. They show that peptides can be made to slow pigment production in a dish. They do not yet show what a cream does on a face, and some promising lab molecules never reach a human trial.
Where this leaves the evidence
Peptides are not where the strong pigmentation evidence is. Three small controlled comparisons support three specific molecules — one supplier-run, one university-run, one of five women — and the remaining human data come from combinations with acids, antioxidants or sunscreen. The treatments with large trial records are a different list, and a dermatologist is the right person to work through it, because the cause of the pigment (sun, hormones, inflammation, a medicine) changes the answer. For the broader picture of what peptides are claimed to do, our peptides for skin explainer covers the main groups, and glutathione for skin covers the other “brightening” ingredient readers ask about.
Sources
PubMed searches run 22 October 2026: hyperpigmentation[tiab] OR melasma[tiab] (12,246); the same with randomized controlled trial[pt] (697) and combined with peptide*[tiab] (5), hydroquinone[tiab] (118), tranexamic acid[tiab] (75), niacinamide[tiab] (14) and azelaic acid[tiab] (10); peptide*[tiab] with hyperpigmentation or melasma and topical, cream or serum (33); oligopeptide-68 (2). Abstracts opened: PMIDs 21896134, 33529350, 29601620, 29956440, 37924217, 41044809, 26833454 and 33133340. Corrections go to the contact page.